Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for home prothrombin time/INR monitoring for anticoagulation management, effective April 15, 2026. Here's what billing teams need to do.

CMS home PT/INR monitoring coverage policy governs Medicare reimbursement for patients who self-test their clotting levels at home while on anticoagulant therapy like warfarin. This modification updates the criteria under which home INR monitoring is covered—and if your practice manages anticoagulation patients on Medicare, this change affects your billing directly. The policy document does not list specific CPT or HCPCS codes in the available data, but the procedures typically associated with this coverage area include home PT/INR device use and associated testing services. Review your charge capture setup before April 15, 2026.


Quick-Reference Table

Field Detail
Payer CMS (Centers for Medicare & Medicaid Services)
Policy Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation Management
Policy Code N/A
Change Type Modified
Effective Date April 15, 2026
Impact Level High
Specialties Affected Cardiology, Internal Medicine, Hematology, Anticoagulation Clinics, Primary Care, DME Suppliers
Key Action Audit your home PT/INR billing and documentation before April 15, 2026 to confirm you meet the updated medical necessity criteria

CMS Home PT/INR Monitoring Coverage Criteria and Medical Necessity Requirements 2026

Home PT/INR monitoring sits at the intersection of durable medical equipment coverage and clinical management services—which is exactly why this CMS coverage policy draws so much billing scrutiny. The coverage exists to allow patients on long-term anticoagulation therapy (primarily warfarin) to test their INR levels at home rather than making repeated clinic visits for lab draws.

Medicare's coverage of home PT/INR monitoring has historically required a specific set of medical necessity criteria. To qualify, patients generally must have a diagnosis that requires long-term anticoagulation therapy. Atrial fibrillation, mechanical heart valve replacement, and venous thromboembolism are the most common qualifying conditions.

Beyond the diagnosis, CMS requires that the patient—or a caregiver—be trained and capable of using the home testing device. Training is a documented requirement, not an assumed one. If your documentation doesn't reflect completed training, that's a claim denial waiting to happen.

Prior authorization is not typically required for home PT/INR monitoring under Medicare, but that doesn't mean you skip the documentation step. Medical necessity must be established and documented in the patient record before you bill. Your ordering physician needs to document the qualifying diagnosis, the plan for long-term anticoagulation, and the rationale for home testing over clinic-based testing.

The modified coverage policy may adjust these thresholds or add documentation requirements. Because the full policy detail wasn't available in the source data at the time of publication, confirm the specific updated criteria directly at the CMS source linked above before April 15, 2026. If you manage a large anticoagulation panel, loop in your compliance officer before the effective date.


CMS Home PT/INR Monitoring Exclusions and Non-Covered Indications

Not every anticoagulation patient qualifies for home monitoring under Medicare. CMS has historically excluded coverage in several situations, and this modified policy likely preserves or tightens those boundaries.

Patients on newer direct oral anticoagulants (DOACs)—apixaban, rivaroxaban, dabigatran, edoxaban—do not require INR monitoring. The PT/INR test is not clinically relevant for these drugs. Billing home PT/INR monitoring for a patient on a DOAC is not just a claim denial risk—it's a potential false claim.

Short-term anticoagulation therapy is also generally excluded. If a patient is on warfarin for a defined, limited period (such as post-surgical DVT prophylaxis), home monitoring coverage does not apply. Long-term therapy is the key qualifier.

CMS also excludes coverage when the patient lacks the cognitive or physical ability to perform self-testing and there is no trained caregiver available. Documentation of patient or caregiver capability is part of the medical necessity record.


Coverage Indications at a Glance

The following table reflects the historically established coverage framework for this policy. Because the full modified policy detail was not available in the source data, treat this as a baseline and verify updates against the CMS source before billing after April 15, 2026.

Indication Status Relevant Codes Notes
Long-term anticoagulation with warfarin — atrial fibrillation Covered Not listed in source data Requires documented diagnosis and training
Long-term anticoagulation with warfarin — mechanical heart valve Covered Not listed in source data Among the strongest qualifying diagnoses
Long-term anticoagulation with warfarin — venous thromboembolism Covered Not listed in source data Must be long-term, not short-course therapy
+ 3 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

This policy is now in effect (since 2026-04-15). Verify your claims match the updated criteria above.

CMS Home PT/INR Monitoring Billing Guidelines and Action Items 2026

Here's what your billing team and clinical documentation staff should do before April 15, 2026.

#Action Item
1

Pull the updated policy from the CMS source. The policy data available at publication time did not include the full modified text. Go directly to the source (linked above) and read the updated criteria line by line. Don't rely on your current workflow until you've confirmed it still aligns.

2

Audit your active home PT/INR patients for documentation completeness. For every Medicare patient currently billed under this coverage policy, confirm that the chart shows: a qualifying long-term anticoagulation diagnosis, documented patient or caregiver training, and the ordering physician's medical necessity rationale. Missing any one of these is enough to trigger a claim denial.

3

Confirm that billed patients are actually on warfarin—not a DOAC. This sounds obvious, but medication changes happen. A patient who switched from warfarin to apixaban six months ago should not have ongoing home PT/INR claims running. Cross-reference your billing against the current medication list.

+ 3 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

If your practice or organization manages a high volume of anticoagulation patients, the financial exposure here is real. Talk to your billing consultant or compliance officer before the effective date if anything in the modified policy is unclear.


Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Home PT/INR Monitoring Under This Policy

Important note: The policy source data provided does not include specific CPT, HCPCS, or ICD-10 codes. Do not use the codes below as an authoritative billing list—these are the codes commonly associated with home PT/INR monitoring based on industry knowledge. Verify the exact codes against the full modified policy at the CMS source before billing.

Commonly Associated Codes — Verify Before Use

Code Type Description
Not listed in policy source data Pull exact codes from the CMS policy document before April 15, 2026

The real issue here is that home PT/INR monitoring billing involves at least two distinct code categories: the home testing device (typically a HCPCS code for DME) and the test strips or reagents (also typically HCPCS). Some practices also bill evaluation and management codes for anticoagulation management visits. Each of these has a different coverage framework and documentation requirement.

Without confirmed codes from the modified policy, billing teams should not assume prior-period codes are still valid. CMS policy modifications can add, remove, or reclassify covered codes. Treat the April 15, 2026 effective date as a hard cutoff—pull the confirmed code list before that date and update your charge capture accordingly.

If your Medicare Administrative Contractor (MAC) has issued a local coverage determination (LCD) that overlaps with this national policy, the more restrictive criteria apply. Check with your MAC to confirm whether any regional policy changes accompany this national modification.


Get the Full Picture

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee